Updates are available Correction dated 2025-03-28
Click to view Correction: https://doi.org/10.1038/s41591-025-03664-0
-
Authors
van Olst, Lynn https://orcid.org/0000-0001-7569-0470
Simonton, Brooke
Edwards, Alex J.
Forsyth, Anne V.
Boles, Jake
Jamshidi, Pouya
Watson, Thomas
Shepard, Nate
Krainc, Talia
Argue, Benney MR https://orcid.org/0009-0009-9799-901X
Zhang, Ziyang
Kuruvilla, Joshua
Camp, Lily https://orcid.org/0009-0002-3032-2791
Li, Mengwei
Xu, Hang
Norman, Jeanette L.
Cahan, Joshua https://orcid.org/0000-0002-9453-733X
Vassar, Robert
Chen, Jinmiao
Castellani, Rudolph J.
Nicoll, James AR https://orcid.org/0000-0002-9444-7246
Boche, Delphine https://orcid.org/0000-0002-5884-130X
Gate, David https://orcid.org/0000-0003-0481-9657
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS112458)
BrightFocus Foundation (A2023003S)
Alzheimer's Association (23AARG-1026607)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG078713)
Alzheimer Nederland (WE.06-2023-03)
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 6 February 2025
First Online: 6 March 2025
Change Date: 28 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03664-0
Competing interests
: J.A.R.N. has been a consultant/advisor relating to AD immunization programs for Elan Pharmaceuticals, GlaxoSmithKline, Novartis, Roche, Janssen, Pfizer, Biogen and Eisai. D.B. has been a consultant/advisor relating to AD immunization programs for Elan Pharmaceuticals and Biogen. D.G. has been a consultant/advisor relating to AD therapies for Merck and Novo Nordisk. They have no financial interest in relation to AD immunotherapy. The other authors declare no competing interests.
